AREG and neoplasm: This approach not only alleviated the reduction of T cell proliferation and cytotoxic activity induced by the binding of tumor cell PD‐L1 to T cell PD‐1, but also inhibited the excessive proliferation of tumor cells triggered by the activation of the EGFR pathway via ligands such as EGF and amphiregulin.